Orthocell see 89% of patients return to work pain-free
[videojs_hls url=’//du7x25at22z7c.cloudfront.net/263856/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/Headlines06_360_190904.jpg’]
Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per cent of patients return to work and recreation pain-free.
A review of patients who completed the trial confirmed all patients achieved a successful tendon repair with no revision surgeries reported.
CelGro® strengthens rotator cuff tendon repair in the shoulder.
No revision surgeries were reported at two years after CelGro® tendon regeneration surgery.
It's now shown to improve nerve, tendon and bone repair.
Shares in Orthocell (ASX:OCC) are trading 10.13 per cent higher at $0.43.
Copyright 2019 – Finance News Network
Source: Finance News Network
